Arvinas, Inc. (ARVN)
7.515
+0.06
(+0.87%)
USD |
NASDAQ |
Oct 08, 16:00
7.515
0.00 (0.00%)
After-Hours: 20:00
Arvinas Net Income (Quarterly) : 169.40M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 169.40M |
| March 31, 2026 | -57.60M |
| December 31, 2025 | -67.40M |
| September 30, 2025 | -35.10M |
| June 30, 2025 | -61.20M |
| March 31, 2025 | 82.90M |
| December 31, 2024 | -45.10M |
| September 30, 2024 | -49.20M |
| June 30, 2024 | -35.20M |
| March 31, 2024 | -69.40M |
| December 31, 2023 | -154.80M |
| September 30, 2023 | -64.00M |
| June 30, 2023 | -66.60M |
| March 31, 2023 | -81.90M |
| December 31, 2022 | -82.90M |
| September 30, 2022 | -66.20M |
| June 30, 2022 | -70.00M |
| March 31, 2022 | -63.40M |
| December 31, 2021 | -53.00M |
| Date | Value |
|---|---|
| September 30, 2021 | -46.75M |
| June 30, 2021 | -50.29M |
| March 31, 2021 | -40.96M |
| December 31, 2020 | -41.55M |
| September 30, 2020 | -30.82M |
| June 30, 2020 | -25.23M |
| March 31, 2020 | -21.74M |
| December 31, 2019 | -21.05M |
| September 30, 2019 | -17.68M |
| June 30, 2019 | -17.16M |
| March 31, 2019 | -14.40M |
| December 31, 2018 | -16.09M |
| September 30, 2018 | -13.39M |
| June 30, 2018 | -7.854M |
| March 31, 2018 | -4.150M |
| December 31, 2017 | -4.728M |
| September 30, 2017 | -6.397M |
| June 30, 2017 | -6.678M |
| March 31, 2017 | -6.246M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Cocrystal Pharma, Inc. | -3.164M |
| CNBX Pharmaceuticals, Inc. | -0.1542M |
| Fulcrum Therapeutics, Inc. | -26.18M |
| Definium Therapeutics, Inc. | -158.99M |
| LeonaBio, Inc. | -19.01M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 249.70M |
| Total Expenses (Quarterly) | 80.30M |
| EPS Diluted (Quarterly) | 2.578 |
| Enterprise Value | -73.22M |
| Gross Profit Margin (Quarterly) | 95.92% |
| Profit Margin (Quarterly) | 67.84% |
| Earnings Yield | 2.13% |
| Normalized Earnings Yield | 2.911 |